SCHEMBL7749343

SCHEMBL7749343

CCCN(CCC)[C@@H]1CCc2c(F)ccc(O)c2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 1.00
HTR1A P08908 5/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2D6 P10635 2/20 1.00
TSHR P16473 2/20 1.00
PKM P14618 1/20 1.00
ALOX15 P16050 1/20 1.00
MAPK1 P28482 1/20 1.00
LMNA P02545 2/20 0.97
PMP22 Q01453 2/20 0.97
GLA P06280 1/20 0.97
APEX1 P27695 1/20 0.97
KMT2A Q03164 1/20 0.97
FYN P06241 1/20 0.68
DRD3 P35462 6/20 0.61
HTR7 P34969 4/20 0.61
DRD4 P21917 3/20 0.61
DRD1 P21728 2/20 0.61
HTR1D P28221 2/20 0.61
DRD5 P21918 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29386657 1.00 DRD2 (1.00) DRD2HTR1ACYP1A2CYP2D6TSHR
SCHEMBL5658541 1.00 DRD2 (1.00) DRD2HTR1ACYP1A2CYP2D6TSHR
SCHEMBL5658545 1.00 DRD2 (1.00) DRD2HTR1ACYP1A2CYP2D6TSHR
Bromide SCHEMBL29496166 0.99 DRD2 (0.97) DRD2HTR1ACYP1A2CYP2D6TSHR
Hydrochloric Acid SCHEMBL5962618 0.99 LMNA (1.00) DRD2HTR1ACYP1A2CYP2D6TSHR
Bromide SCHEMBL9064205 0.99 DRD2 (0.97) DRD2HTR1ACYP1A2CYP2D6TSHR
SCHEMBL14283976 0.90 DRD2 (0.81) DRD2HTR1ACYP1A2CYP2D6TSHR
SCHEMBL9862321 0.83 DRD2 (0.71) DRD2HTR1ACYP1A2CYP2D6TSHR
SCHEMBL15657500 0.83 DRD2 (0.71) DRD2HTR1ACYP1A2CYP2D6TSHR
Hydrochloric Acid SCHEMBL9424658 0.82 LMNA (0.72) DRD2HTR1ACYP1A2CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001034124-A2 USE OF 5HT-1A-SEROTONINE RECEPTOR AGONISTS FOR TREATING GENETIC OR FUNCTIONAL RHYTHM DISORDERS IN THE RESPIRATORY SYSTEM RICHTER DIETHELM WOLFGANG (DE) 2001-05-17 WO claimed
US-20240165032-A1 DRUG DELIVERY SYSTEM EB IP HYBRITABS B V (NL) 2024-05-23 US disclosed
US-20230330028-A1 PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS EB IP HYBRITABS B.V. (NL) 2023-10-19 US disclosed
CN-109414402-B Method for preparing a drug delivery system with a testosterone compound present externally or topically and such a drug delivery system EB IP希博里塔布斯有限责任公司 2022-11-04 CN disclosed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS HTR6, GAP43, HTR5A DRD2 242/4885HTR1A 7/4885CYP1A2 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.